Compare
Bioventus Inc. vs UFP Technologies Inc vs AtriCure, Inc. vs Glaukos Corp
| Latest fiscal year | Bioventus Inc. BVS | UFP Technologies Inc UFPT | AtriCure, Inc. ATRC | Glaukos Corp GKOS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $568.09M | $602.80M | $534.53M | $507.44M |
| Revenue growth (YoY) | -0.9% | +19.5% | +14.9% | +32.3% |
| Gross margin | 68.3% | 28.3% | 75.0% | 55.7% |
| Operating margin | 9.5% | 15.3% | -1.8% | -39.3% |
| Net margin | 4.0% | 11.3% | -2.1% | -37.0% |
| Net income | $22.73M | $68.31M | -$11.45M | -$187.69M |
| EPS (Diluted) | $0.33 | $8.75 | -$0.24 | -$3.28 |
| Operating cash flow | $74.67M | $91.91M | $57.33M | -$14.79M |
| Free cash flow | $72.11M | n/a | $48.28M | -$22.45M |
| Cash & equivalents | $51.24M | $20.30M | $167.43M | $90.81M |
| Total assets | $683.56M | $655.08M | $654.18M | $893.49M |
| Total liabilities | $455.11M | $231.20M | $162.24M | $237.33M |
| Shareholders' equity | $184.10M | $423.88M | $491.94M | $656.15M |
| Return on year-end equity | 12.3% | 16.1% | -2.3% | -28.6% |
| Shares outstanding | n/a | 7.71M | 49.79M | 57.51M |
Revenue, most recent five fiscal years
| Fiscal year | Bioventus Inc. | UFP Technologies Inc | AtriCure, Inc. | Glaukos Corp |
|---|---|---|---|---|
| Latest | $568.09M Ended 2025-12-31 | $602.80M Ended 2025-12-31 | $534.53M Ended 2025-12-31 | $507.44M Ended 2025-12-31 |
| 1 year earlier | $573.28M Ended 2024-12-31 | $504.42M Ended 2024-12-31 | $465.31M Ended 2024-12-31 | $383.48M Ended 2024-12-31 |
| 2 years earlier | $512.35M Ended 2023-12-31 | $400.07M Ended 2023-12-31 | $399.25M Ended 2023-12-31 | $314.71M Ended 2023-12-31 |
| 3 years earlier | $512.12M Ended 2022-12-31 | $353.79M Ended 2022-12-31 | $330.38M Ended 2022-12-31 | $282.86M Ended 2022-12-31 |
| 4 years earlier | $430.90M Ended 2021-12-31 | $206.32M Ended 2021-12-31 | $274.33M Ended 2021-12-31 | $294.01M Ended 2021-12-31 |